Intravesical epinephrine preserves uroplakin II expression in urinary bladder from cyclophosphamide-induced rat cystitis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Kyung YS;Kyung YS; Park H; Lee G
  • Source:
    Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2012 Aug; Vol. 385 (8), pp. 769-76. Date of Electronic Publication: 2012 May 27.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin, New York, Springer Verlag.
    • Subject Terms:
      Alkylating Agents* ; Cyclophosphamide*; Adrenergic Agonists/*pharmacology ; Cystitis/*metabolism ; Epinephrine/*pharmacology ; Urinary Bladder/*metabolism ; Uroplakin II/*biosynthesis; Administration, Intravesical ; Adrenergic alpha-1 Receptor Agonists/pharmacology ; Animals ; Cystitis/chemically induced ; Female ; Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism ; Immunohistochemistry ; Microscopy, Electron, Scanning ; RNA, Messenger/biosynthesis ; RNA, Messenger/genetics ; Rats ; Rats, Sprague-Dawley ; Real-Time Polymerase Chain Reaction ; Receptors, Adrenergic, alpha-1/biosynthesis ; Urinary Bladder/drug effects ; Urinary Catheterization ; Uroplakin II/antagonists & inhibitors
    • Abstract:
      We investigated the attenuated effect of intravesical epinephrine (EPI) on uroplakin II (UPII) expression in cyclophosphamide (CYP)-induced rat cystitis. Sixty-eight Sprague-Dawley female rats were divided into one negative control group (GI) and five intraperitoneally CYP (150 mg CYP/kg)-injected groups (GII-VI) consisting of a positive control group (GII), three groups (GIII-V) with retaining intravesically instillated ameliorating agents for 90 min by urethral ligation until sacrifice, and one group (GVI) with freely voiding after intravesical EPI instillation. The retention groups were further classified into null-treated- (GIII), EPI- (GIV), and vehicle group (GV). All rats were euthanized 24 h after CYP injection. The UPII and α1-adrenergic receptors (AR) levels were measured with real-time polymerase chain reaction (RT-PCR) method and the morphological changes were also evaluated. CYP induced severe cystitis and decreased vesical UPII mRNA level. The EPI-treated groups had showed attenuation effects against submucosal edema and hemorrhage, and preserved UPII expression. Concurrently, intravesical EPI resulted in a significant preservation of both subtypes of α1A- and α1B AR expressions, which was well correlated with the hemostatic pattern in the samples. The obstructed and null-treated group (GIII) revealed severe cystitis and maximally decreased UPII levels, and the diluting effect of vehicle (GV) on CYP toxicity was insignificant on UPII preservation. The UPII level of RT-PCR was well correlated with the UPII immunohistological expression and their morphological changes. Intravesical instillation of EPI preserves UPII expression and attenuates the toxic responses in the bladder in CYP-induced rat cystitis.
    • References:
      J Korean Med Sci. 2009 Aug;24(4):684-9. (PMID: 19654953)
      Leuk Lymphoma. 2008 Feb;49(2):227-36. (PMID: 18231908)
      Exp Biol Med (Maywood). 2007 Apr;232(4):565-70. (PMID: 17392493)
      Biochem Pharmacol. 1979 Jul 1;28(13):2045-9. (PMID: 475846)
      J Biol Chem. 1995 Dec 15;270(50):29752-9. (PMID: 8530366)
      J Clin Oncol. 1989 Sep;7(9):1208-16. (PMID: 2504890)
      J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jun 25;806(1):59-63. (PMID: 15149612)
      Urology. 2006 Mar;67(3):636-41. (PMID: 16527596)
      J Biol Chem. 1990 Nov 5;265(31):19170-9. (PMID: 2229070)
      Arch Toxicol. 2011 Jan;85(1):51-7. (PMID: 20186394)
      N Engl J Med. 1983 Dec 1;309(22):1347-53. (PMID: 6355849)
      Lab Invest. 1967 Jan;16(1):44-65. (PMID: 4164460)
      Mayo Clin Proc. 1992 Feb;67(2):128-30. (PMID: 1545575)
      BJU Int. 2001 Sep;88 Suppl 2:27-34; discussion 49-50. (PMID: 11589667)
      Bone Marrow Transplant. 1998 Sep;22(5):485-90. (PMID: 9733272)
      Bone Marrow Transplant. 2003 May;31(10):923-5. (PMID: 12748670)
      J Cancer Res Clin Oncol. 1995;121(2):128-31. (PMID: 7883776)
      Neurosci Lett. 2007 Jun 29;421(3):250-2. (PMID: 17574748)
      Lab Invest. 1981 Feb;44(2):89-96. (PMID: 7464042)
      J Cell Biol. 2000 Nov 27;151(5):961-72. (PMID: 11085999)
      Mol Pharmacol. 1979 Sep;16(2):441-8. (PMID: 229399)
    • Accession Number:
      0 (Adrenergic Agonists)
      0 (Adrenergic alpha-1 Receptor Agonists)
      0 (Alkylating Agents)
      0 (RNA, Messenger)
      0 (Receptors, Adrenergic, alpha-1)
      0 (Uroplakin II)
      8N3DW7272P (Cyclophosphamide)
      EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases)
      YKH834O4BH (Epinephrine)
    • Publication Date:
      Date Created: 20120529 Date Completed: 20121126 Latest Revision: 20211021
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s00210-012-0761-z
    • Accession Number:
      22638760